	US 11,752,096 B2
	Targeted delivery of anti-CSF1R antibodies to joints with tenosynovial giant cell tumors
Laman Alani, Menlo Park, CA (US); Kirk William Johnson, Moraga, CA (US); Michael Huang, Redwood City, CA (US); and Chung-Chiang Hsu, Los Altos Hills, CA (US)
Assigned to AmMax Bio, Inc., Redwood City, CA (US)
Filed by AmMax Bio, Inc., Redwood City, CA (US)
Filed on Aug. 22, 2022, as Appl. No. 17/821,459.
Application 17/821,459 is a continuation of application No. PCT/US2022/074928, filed on Aug. 12, 2022.
Claims priority of provisional application 63/232,611, filed on Aug. 12, 2021.
Prior Publication US 2023/0065193 A1, Mar. 2, 2023
Int. Cl. A61K 9/00 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61P 19/02 (2006.01); A61K 39/00 (2006.01)

CPC A61K 9/0019 (2013.01) [A61P 19/02 (2018.01); A61P 35/00 (2018.01); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01)]

18 Claims

1. A method for administering an anti-CSF1R (colony stimulating factor 1 receptor) antibody to a mammalian subject, comprising local administration of a composition comprising the antibody at or proximate to a tissue in the mammalian subject, wherein the tissue is a joint impacted with tenosynovial giant cell tumor (TGCT), and wherein the tissue comprises at least a cell that expresses CSF1R on the surface.

11. A method for treating tenosynovial giant cell tumor (TGCT) at a joint in a patient, comprising administering an anti-CSF1R (colony stimulating factor 1 receptor) antibody at or proximate to the TGCT at the joint in the patient.